NeoGenomics, Inc.
12701 Commonwealth Drive
Suite 9
Fort Myers
Florida
33913
United States
Tel: 239-768-0600
Fax: 239-768-0711
Website: http://www.neogenomics.org/
Email: info@neogenomics.org
268 articles about NeoGenomics, Inc.
-
NeoGenomics Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
1/5/2021
NeoGenomics, Inc. (NASDAQ:NEO) a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced that it has commenced proposed underwritten public offerings of approximately $200,000,000 of newly issued shares of common stock and $250,000,000 aggregate principal amount of convertible senior notes due 2028
-
NeoGenomics To Virtually Participate In The 39th Annual J.P. Morgan Healthcare Conference
1/4/2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, Dr. Lawrence Weiss, Chief Medical Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the virtual 39 th Annual J.P. Morgan Healthcare Conference 2
-
NeoGenomics To Virtually Participate In Fireside Chat At The Stephens Annual Investment Conference 2020
11/13/2020
NeoGenomics, Inc. announced that Doug VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer, will be participating in a virtual fireside chat at the Stephens Annual Investment Conference 2020 on Tuesday, November 17, 2020 at 9:00am ET.
-
NeoGenomics to Offer Mobile Phlebotomy Services for Liquid Biopsy Tests
11/9/2020
NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today the launch of a mobile phlebotomy service for its blood-based tests, including InVisionFirst Lung, its advanced non-small cell lung cancer liquid biopsy test,
-
NeoGenomics Reports Revenue Growth of 20% to Record $125 Million in the Third Quarter
10/27/2020
NeoGenomics, Inc., a leading provider of cancer-focused genetics testing services, announced its third-quarter results for the period ended September 30, 2020.
-
NeoGenomics Announces Plans to Expand Global Footprint in Pharma Services by Opening Clinical Research Laboratory in Suzhou, China
10/13/2020
NeoGenomics continues to build its world-class pharma clinical research capabilities to include servicing Greater China-based clinical trials
-
NeoGenomics Schedules Its Third Quarter Earnings Release for October 27, 2020
10/1/2020
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced that it plans to release its third quarter 2020 financial results on Tuesday, October 27, 2020.
-
NeoGenomics Reports Revenue of $87 Million in the Second Quarter amid COVID-19 Pandemic
7/28/2020
Second-Quarter 2020 Results and Highlights
-
NeoGenomics Announces Board Appointments
7/20/2020
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced changes in the composition and certain roles of its Board of Directors.
-
NeoGenomics, Inc. announced today that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020
7/1/2020
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020.
-
NeoGenomics Schedules its Second Quarter Earnings Release for July 28, 2020
7/1/2020
FT. MYERS, FL / ACCESSWIRE / July 1, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020. The Company has scheduled a web-cast and conference call to discuss their first quarter results on Tuesday, July 28, 2020 at 8:30 AM EDT.
-
Bayer and NeoGenomics Launch the Test4TRK™ Program to Provide Genomic Cancer Testing at No Cost for People Living with Advanced Thyroid and Colorectal Cancers
5/5/2020
Bayer to cover testing costs for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) The results of a genomic cancer test can help healthcare providers determine appropriate treatment plans for people with an NTRK gene fusion NTRK gene fusions can drive tumor growth and are more common in MSI-H mCRC and RAI-R DTC cases than other subt
-
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
11/30/2018
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeoGenomics, Inc. (NASDAQ: NEO) today announced a master service agreement to accelerate the availability of innovative companion diagnostics that enable precision medicine for cancer patients
-
NeoGenomics Europe S.A. Opens Its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials
11/9/2017
NeoGenomics opened the doors of its new Rolle, Switzerland facility on Wednesday, November 8th to bring its unique Pharma Services offering to the global research community.
-
NeoGenomics Announces the Opening of Its First International Laboratory near Geneva, Switzerland to Support Clinical Trials
10/26/2017
NeoGenomics Announces the Opening of its First International Laboratory near Geneva, Switzerland to Support Clinical Trials FT. MYERS, FL--(Marketwired - October 24, 2017) - NeoGenomics, Inc. ( NASDAQ : NEO ) , a leading provider of cancer-focused genetic testing services in the United States, announced today that it has opened its first international laboratory facility in Rolle, Switzerland, in the Canton of Vaud, just outside of Geneva as a separate subsidiary, NeoGenomics Euro
-
NeoGenomics Schedules Its Q3 2017 Earnings Release For October 25, 2017
10/2/2017
-
NeoGenomics Reports Record Revenue Of $66.1 Million On 16% Volume Growth And 13% Reduction In Average Cost Per Test In The Second Quarter Of 2017
7/25/2017
-
NeoGenomics And Definiens AG Enter Into Agreement To Develop Novel Assays For Clinical Trials & Clinical Testing
3/13/2017
-
NeoGenomics Closes $150 Million Senior Credit Facility
12/22/2016
-
NeoGenomics Reports 142% Revenue Growth To $60.8 Million And A Record $9.6 Million In Cash Flow From Operations In The Third Quarter Of 2016
10/26/2016